Research ExplorerPublicationsRandomized double blind comparison of olanzapine vs. clozapi...

Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.

Standard

Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. / Naber, Dieter; Riedel, M; Klimke, A; Vorbach, E-U; Lambert, Martin; Kühn, K-U; Bender, S; Bandelow, B; Lemmer, W; Moritz, Steffen; Dittmann, R W.

In: ACTA PSYCHIAT SCAND, Vol. 111, No. 2, 2, 2005, p. 106-115.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Naber, D, Riedel, M, Klimke, A, Vorbach, E-U, Lambert, M, Kühn, K-U, Bender, S, Bandelow, B, Lemmer, W, Moritz, S & Dittmann, RW 2005, 'Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.', ACTA PSYCHIAT SCAND, vol. 111, no. 2, 2, pp. 106-115. <http://www.ncbi.nlm.nih.gov/pubmed/15667429?dopt=Citation>

APA

Naber, D., Riedel, M., Klimke, A., Vorbach, E-U., Lambert, M., Kühn, K-U., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., & Dittmann, R. W. (2005). Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. ACTA PSYCHIAT SCAND, 111(2), 106-115. [2]. http://www.ncbi.nlm.nih.gov/pubmed/15667429?dopt=Citation

Vancouver

Naber D, Riedel M, Klimke A, Vorbach E-U, Lambert M, Kühn K-U et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. ACTA PSYCHIAT SCAND. 2005;111(2):106-115. 2.

Bibtex

@article{3a3d9cb5cf4f46f9bde9ecaf301edd44,
title = "Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.",
abstract = "OBJECTIVE: This randomized double-blind multicenter trial evaluated the effects of olanzapine vs. clozapine on subjective well-being, quality of life (QOL) and clinical outcome. METHOD: The primary objective was to demonstrate non-inferiority of olanzapine, mean dosage 16.2 +/- 4.8 (5-25 mg/day) vs. clozapine, mean dosage 209 +/- 91 (100-400 mg/day) regarding improvement on the 'Subjective Well-Being under Neuroleptic Treatment' (SWN) Scale after 26 treatment weeks in 114 patients with schizophrenia. Secondary outcome parameters included: Munich QOL Dimension List (MLDL), Positive and Negative Symptom Scale (PANSS), Clinical Global Impression (CGI). RESULTS: SWN scores improved significantly in both groups, olanzapine was non-inferior to clozapine (group difference 3.2 points in favor of olanzapine; 95% CI: 4.2;10.5). MLDL-satisfaction, PANSS and CGI-S improved similarly, olanzapine yielded a higher CGI Therapeutic Index. Individual SWN and PANSS changes correlated only moderately (r = -0.45). CONCLUSION: Olanzapine was non-inferior to clozapine. The lack of a marked correlation between PANSS and SWN improvements indicates that patients and psychiatrists perceive treatment differently.",
author = "Dieter Naber and M Riedel and A Klimke and E-U Vorbach and Martin Lambert and K-U K{\"u}hn and S Bender and B Bandelow and W Lemmer and Steffen Moritz and Dittmann, {R W}",
year = "2005",
language = "Deutsch",
volume = "111",
pages = "106--115",
journal = "ACTA PSYCHIAT SCAND",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.

AU - Naber, Dieter

AU - Riedel, M

AU - Klimke, A

AU - Vorbach, E-U

AU - Lambert, Martin

AU - Kühn, K-U

AU - Bender, S

AU - Bandelow, B

AU - Lemmer, W

AU - Moritz, Steffen

AU - Dittmann, R W

PY - 2005

Y1 - 2005

N2 - OBJECTIVE: This randomized double-blind multicenter trial evaluated the effects of olanzapine vs. clozapine on subjective well-being, quality of life (QOL) and clinical outcome. METHOD: The primary objective was to demonstrate non-inferiority of olanzapine, mean dosage 16.2 +/- 4.8 (5-25 mg/day) vs. clozapine, mean dosage 209 +/- 91 (100-400 mg/day) regarding improvement on the 'Subjective Well-Being under Neuroleptic Treatment' (SWN) Scale after 26 treatment weeks in 114 patients with schizophrenia. Secondary outcome parameters included: Munich QOL Dimension List (MLDL), Positive and Negative Symptom Scale (PANSS), Clinical Global Impression (CGI). RESULTS: SWN scores improved significantly in both groups, olanzapine was non-inferior to clozapine (group difference 3.2 points in favor of olanzapine; 95% CI: 4.2;10.5). MLDL-satisfaction, PANSS and CGI-S improved similarly, olanzapine yielded a higher CGI Therapeutic Index. Individual SWN and PANSS changes correlated only moderately (r = -0.45). CONCLUSION: Olanzapine was non-inferior to clozapine. The lack of a marked correlation between PANSS and SWN improvements indicates that patients and psychiatrists perceive treatment differently.

AB - OBJECTIVE: This randomized double-blind multicenter trial evaluated the effects of olanzapine vs. clozapine on subjective well-being, quality of life (QOL) and clinical outcome. METHOD: The primary objective was to demonstrate non-inferiority of olanzapine, mean dosage 16.2 +/- 4.8 (5-25 mg/day) vs. clozapine, mean dosage 209 +/- 91 (100-400 mg/day) regarding improvement on the 'Subjective Well-Being under Neuroleptic Treatment' (SWN) Scale after 26 treatment weeks in 114 patients with schizophrenia. Secondary outcome parameters included: Munich QOL Dimension List (MLDL), Positive and Negative Symptom Scale (PANSS), Clinical Global Impression (CGI). RESULTS: SWN scores improved significantly in both groups, olanzapine was non-inferior to clozapine (group difference 3.2 points in favor of olanzapine; 95% CI: 4.2;10.5). MLDL-satisfaction, PANSS and CGI-S improved similarly, olanzapine yielded a higher CGI Therapeutic Index. Individual SWN and PANSS changes correlated only moderately (r = -0.45). CONCLUSION: Olanzapine was non-inferior to clozapine. The lack of a marked correlation between PANSS and SWN improvements indicates that patients and psychiatrists perceive treatment differently.

M3 - SCORING: Zeitschriftenaufsatz

VL - 111

SP - 106

EP - 115

JO - ACTA PSYCHIAT SCAND

JF - ACTA PSYCHIAT SCAND

SN - 0001-690X

IS - 2

M1 - 2

ER -